Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pia Burman

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
European Journal of Endocrinology|January 10, 2022
Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary RegisterSteinunn Arnardóttir, Jacob Järås, Pia Burman, et al.
Reviews in Endocrine & Metabolic Disorders|June 7, 2020
Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questionsJacqueline Trouillas, Marie-Lise Jaffrain-Rea, Alexandre Vasiljevic, et al.
European Journal of Endocrinology|July 13, 2022
Pituitary function and the response to GH therapy in patients with Langerhans cell histiocytosis: analysis of the KIMS databasePhilippe Touraine, Yempabou Sagna, Anders F Mattsson, et al.
The Journal of Clinical Endocrinology and Metabolism|November 16, 2006
Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performanceRosario Pivonello, Maurizio Galderisi, Renata S Auriemma, et al.
The Journal of Clinical Endocrinology and Metabolism|October 14, 2017
Relative Risks of Contributing Factors to Morbidity and Mortality in Adults With Craniopharyngioma on Growth Hormone ReplacementKevin C J Yuen, Anders F Mattsson, Pia Burman, et al.
The Journal of Clinical Endocrinology and Metabolism|March 31, 2026
Acromegaly is Associated with an Increased Incidence of Primary Malignant Tumors: Data from a National Study in SwedenErika Tsatsaris, Jonas Robèrt, Pia Burman, et al.
European Journal of Endocrinology|August 19, 2008
Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trialsCamilo Jimenez, Pia Burman, Roger Abs, et al.
Clinical Endocrinology|August 20, 2008
Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutationsSusana Igreja, Harvinder S Chahal, Scott A Akker, et al.
European Journal of Endocrinology|February 25, 2006
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose toleranceAnnamaria Colao, Rosario Pivonello, Renata S Auriemma, et al.
Lakartidningen|May 26, 2012
[Traumatic brain injury can cause pituitary deficiency. Suggestions for guidelines for assessment of pituitary function]Thord Rosén, Pia Burman, Per Dahlqvist, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
European Journal of Endocrinology|January 10, 2022
Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary RegisterSteinunn Arnardóttir, Jacob Järås, Pia Burman, et al.
Reviews in Endocrine & Metabolic Disorders|June 7, 2020
Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questionsJacqueline Trouillas, Marie-Lise Jaffrain-Rea, Alexandre Vasiljevic, et al.
European Journal of Endocrinology|July 13, 2022
Pituitary function and the response to GH therapy in patients with Langerhans cell histiocytosis: analysis of the KIMS databasePhilippe Touraine, Yempabou Sagna, Anders F Mattsson, et al.
The Journal of Clinical Endocrinology and Metabolism|November 16, 2006
Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performanceRosario Pivonello, Maurizio Galderisi, Renata S Auriemma, et al.
The Journal of Clinical Endocrinology and Metabolism|October 14, 2017
Relative Risks of Contributing Factors to Morbidity and Mortality in Adults With Craniopharyngioma on Growth Hormone ReplacementKevin C J Yuen, Anders F Mattsson, Pia Burman, et al.
The Journal of Clinical Endocrinology and Metabolism|March 31, 2026
Acromegaly is Associated with an Increased Incidence of Primary Malignant Tumors: Data from a National Study in SwedenErika Tsatsaris, Jonas Robèrt, Pia Burman, et al.
European Journal of Endocrinology|August 19, 2008
Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trialsCamilo Jimenez, Pia Burman, Roger Abs, et al.
Clinical Endocrinology|August 20, 2008
Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutationsSusana Igreja, Harvinder S Chahal, Scott A Akker, et al.
European Journal of Endocrinology|February 25, 2006
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose toleranceAnnamaria Colao, Rosario Pivonello, Renata S Auriemma, et al.
Lakartidningen|May 26, 2012
[Traumatic brain injury can cause pituitary deficiency. Suggestions for guidelines for assessment of pituitary function]Thord Rosén, Pia Burman, Per Dahlqvist, et al.
Pageof 8